New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
08:29 EDTPPHMPeregrine reports supporting data for combining bavituximab with irradiation
Peregrine Pharmaceuticals announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy, or SBRT, showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer, or NSCLC, compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research, or AACR, being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
News For PPHM From The Last 14 Days
Check below for free stories on PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PPHM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use